GLUT 5 Is Not Over-Expressed in Breast Cancer Cells and Patient Breast Cancer Tissues

• Gayatri Gowrishankar,

  Affiliation Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford, California, United States of America

  ⨯
• Sabine Zitzmann-Kolbe,

  Affiliation Bayer Schering Pharma AG, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

  ⨯
• Anitha Junutula,

  Affiliation Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford, California, United States of America

  ⨯
• Robert Reeves,

  Affiliation Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford, California, United States of America

  ⨯
• Jelena Levi,

  Affiliation Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford, California, United States of America

  ⨯
• Ananth Srinivasan,

  Affiliation Bayer Schering Pharma AG, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

  ⨯
• Kjerstin Bruus-Jensen,

  Affiliation Bayer Schering Pharma AG, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

  ⨯
• John Cyr,

  Affiliation Bayer Schering Pharma AG, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

  ⨯
• Ludger Dinkelborg,

  Affiliation Bayer Schering Pharma AG, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany

  ⨯
• Sanjiv S. Gambhir

  * E-mail: sgambhir@stanford.edu

  Affiliations Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford, California, United States of America, Department of Bioengineering and Materials Sciences & Engineering, Stanford, California, United States of America

  ⨯